The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV

Information

  • Research Project
  • 10303987
  • ApplicationId
    10303987
  • Core Project Number
    P01AA029541
  • Full Project Number
    1P01AA029541-01
  • Serial Number
    029541
  • FOA Number
    RFA-AA-20-009
  • Sub Project Id
    9187
  • Project Start Date
    9/10/2021 - 4 years ago
  • Project End Date
    8/31/2026 - 9 months from now
  • Program Officer Name
  • Budget Start Date
    6/1/2021 - 4 years ago
  • Budget End Date
    5/31/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    01
  • Suffix
  • Award Notice Date
    9/9/2021 - 4 years ago

The Role of Alcohol Use in Lung Disease After Treatment for Active TB Disease Among Persons Living with HIV

ABSTRACT Tuberculosis (TB) is the leading cause of death from a single infectious agent and the leading cause of death in people living with HIV (PLWH). An estimated 8.5 million people with TB are cured every year but many do not return to full health. Up to half of those completing treatment for pulmonary TB have post-TB lung disease, a disabling under-diagnosed group of lung deficits. Lung deficits at TB treatment completion are the strongest predictors of post-TB lung disease severity up to a year later. Alcohol and HIV are associated with lung immune dysfunction and alcohol use is associated with delayed TB diagnosis, increasing the risk of lung injury during active TB disease. However, it is not known whether alcohol use is associated with post-TB lung disease in PLWH. We hypothesize that hazardous drinking increases susceptibility to and worsens post-TB lung disease in PLWH. Our objective is to investigate hazardous drinking (Alcohol Use Disorders Identification Test [AUDIT] ?8) as a modifiable risk factor for post-TB lung disease in PLWH. To achieve this, we propose a 2-year observational study of 200 PLWH completing inpatient pulmonary TB treatment in St. Petersburg, Russia. We will evaluate the following post-TB lung disease outcomes: functional exercise capacity (primary outcome assessed by 6-minute walk distance), lung physiology (pulmonary function tests), anatomy (CT scan), and lung infections. The primary exposure is past-year hazardous drinking. Secondary alcohol measures will include 30-day Timeline Followback (calendar-based method of alcohol use recall) and phosphatidylethanol (PEth; a biomarker of recent alcohol use). Our expertise spans alcohol use, HIV, TB, pulmonology, epidemiology, and biostatistics. Our primary aim (Aim 1a) is to determine the relationship between past-year hazardous drinking and post-TB lung disease. In Aim 1b we assess the association of past-month heavy drinking and post-TB lung disease progression over time. In Aim 1c we explore whether smoking modifies the association of past-month heavy drinking and post-TB lung disease progression over time. Heavy drinking in Aims 1b and 1c is defined by Timeline Followback as ?7 drinks/week (women) or ?14 drinks/week (men) or PEth>200 ng/mL. In Aim 2, we will qualitatively evaluate factors that can improve tailoring of pharmaco- behavioral alcohol and smoking interventions in PLWH receiving TB treatment. We will conduct in-depth interviews with 24 PLWH during or after inpatient TB treatment and 12 TB healthcare providers. IMPACT: We will determine the association of alcohol use and post-TB lung disease in PLWH. Our quantitative and qualitative data will lay the foundation for future work to tailor alcohol and smoking interventions to improve long-term health in HIV/TB co-infection.

IC Name
NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM
  • Activity
    P01
  • Administering IC
    AA
  • Application Type
    1
  • Direct Cost Amount
    365342
  • Indirect Cost Amount
    94639
  • Total Cost
  • Sub Project Total Cost
    459981
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIAAA:459981\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZAA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    BOSTON MEDICAL CENTER
  • Organization Department
  • Organization DUNS
    005492160
  • Organization City
    BOSTON
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    021182908
  • Organization District
    UNITED STATES